Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: This study was conducted to evaluate the recent prevalence and trend of anti-tuberculosis (TB) drug resistance with a focus on multidrug-resistance (MDR) and fluoroquinolone resistance in South Korea. Methods: We retrospectively reviewed the drug susceptibility testing results of culture-confirmed Mycobacterium tuberculosis isolates collected from 2010 to 2014 at seven tertiary hospitals in South Korea. Results: A total of 5,599 cases were included: 4,927 (88.0%) were new cases and 672 (12.0%) were previously treated cases. The MDR rate has significantly decreased from 6.0% in 2010 to 3.0% in 2014 among new cases, and from 28.6% in 2010 to 18.4% in 2014 among previously treated cases (p < 0.001 and p = 0.027, respectively). The resistance rate to any f luoroquinolone was 0.8% (43/5,221) in non-MDR-TB patients, as compared to 26.2% (99/378) in MDR-TB patients (p < 0.001). There was no significant change in the trend of fluoroquinolone resistance among both non- MDR-TB and MDR-TB patients. Among the 43 non-MDR-TB patients with fluoroquinolone resistance, 38 (88.4%) had fluoroquinolone mono-resistant isolates. Conclusions: The prevalence of MDR-TB has significantly decreased from 2010 to 2014. The prevalence of fluoroquinolone resistance among non-MDR-TB patients was low, but the existence of fluoroquinolone mono-resistant TB may be a warning on the widespread use of fluoroquinolone in the community.
Abstract
Background/Aims: This study was conducted to evaluate the recent prevalence and trend of anti-tuberculosis (TB) drug resistance with a focus on multidrug-resistance (MDR) and fluoroquinolone resistance in South Korea. Methods: We retrospectively reviewed the drug susceptibility testing results of culture-confirmed Mycobacterium tuberculosis isolates collected from 2010 to 2014 at seven tertiary hospitals in South Korea. Results: A total of 5,599 cases were included: 4,927 (88.0%) were new cases and 672 (12.0%) were previously treated cases. The MDR rate has significantly decreased from 6.0% in 2010 to 3.0% in 2014 among new cases, and from 28.6% in 2010 to 18.4% in 2014 among previously treated cases (p < 0.001 and p = 0.027, respectively). The resistance rate to any f luoroquinolone was 0.8% (43/5,221) in non-MDR-TB patients, as compared to 26.2% (99/378) in MDR-TB patients (p < 0.001). There was no significant change in the trend of fluoroquinolone resistance among both non- MDR-TB and MDR-TB patients. Among the 43 non-MDR-TB patients with fluoroquinolone resistance, 38 (88.4%) had fluoroquinolone mono-resistant isolates. Conclusions: The prevalence of MDR-TB has significantly decreased from 2010 to 2014. The prevalence of fluoroquinolone resistance among non-MDR-TB patients was low, but the existence of fluoroquinolone mono-resistant TB may be a warning on the widespread use of fluoroquinolone in the community.
참고문헌 (30)
- Dheda K, "The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis", Lancet Respir Med, 5, pp.291~360 (2017)
- Bai GH, "Trend of anti-tuberculosis drug resistance in Korea, 1994-2004", Int J Tuberc Lung Dis, 11, pp.571~576 (2007)
- 김병주, "국내 다제내성 결핵의 실태", Tuberculosis and Respiratory Diseases, 60(4), pp.404~411 (2006), 대한결핵및호흡기학회
- 김선영, "국내 다제내성 및 광범위내성결핵의 최근 현황", Tuberculosis and Respiratory Diseases, 68(3), pp.146~154 (2010), 대한결핵및호흡기학회
- Johnston JC, "Treatment outcomes of multidrug-resistant tuberculosis:a systematic review and meta-analysis", PLoS One, 4, pp.e6914~ (2009)
- Ahuja SD, "Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes : an individual patient data meta-analysis of 9, 153 patients", PLoS Med, 9, pp.e1001300~ (2012)
- Falzon D, "Resistance to fluoroquinolones and second-line injectable drugs : impact on multidrug-resistant TB outcomes", Eur Respir J, 42, pp.156~168 (2013)
- "Global tuberculosis report 2016" (2018)[URL]
- Zignol M, "Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones : results from a multicountry surveillance project", Lancet Infect Dis, 16, pp.1185~1192 (2016)
- "Korean Guidelines for Tuberculosis" (2005)[URL]
- 목정하, "Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design", Journal of Korean Medical Science, 32(4), pp.636~641 (2017), 대한의학회
- "Definitions and reporting framework for tuberculosis: 2013 revision" (2018)[URL]
- "Annual report on the notified tuberculosis patients in Korea 2016" (2017)[URL]
- Kim DH, "Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis", Am J Respir Crit Care Med, 178, pp.1075~1082 (2008)
- Kwak N, "Changes in treatment outcomes of multidrug-resistant tuberculosis", Int J Tuberc Lung Dis, 19, pp.525~530 (2015)
- Jeong BH, "Outcomes of pulmonary MDR-TB : impacts of fluoroquinolone resistance and linezolid treatment", J Antimicrob Chemother, 70, pp.3127~3133 (2015)
- Kang YA, "Choice between Levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes", Ann Am Thorac Soc, 13, pp.364~370 (2016)
- Ho J, "Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates", Int J Infect Dis, 26, pp.149~153 (2014)
- Gunther G, "Multidrug-resistant tuberculosis in Europe, 2010-2011", Emerg Infect Dis, 21, pp.409~416 (2015)
- Chien JY, "Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan", Clin Infect Dis, 56, pp.1054~1055 (2013)
- Park IN, "Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis", Int J Tuberc Lung Dis, 11, pp.319~324 (2007)
- Huang TS, "Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre : 1995-2003", J Antimicrob Chemother, 56, pp.1058~1062 (2005)
- 김창기, "Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs", Annals of Laboratory Medicine, 37(4), pp.323~326 (2017), 대한진단검사의학회
- Long R, "Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis", Clin Infect Dis, 48, pp.1354~1360 (2009)
- Devasia RA, "Fluoroquinolone resistance in Mycobacterium tuberculosis : the effect of duration and timing of fluoroquinolone exposure", Am J Respir Crit Care Med, 180, pp.365~370 (2009)
- Migliori GB, "Protecting the tuberculosis drug pipeline : stating the case for the rational use of fluoroquinolones", Eur Respir J, 40, pp.814~822 (2012)
- Selvakumar N, "High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India", PLoS One, 10, pp.e0117421~ (2015)
- Jabeen K, "Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014 : implications for disease control", Int J Mycobacteriol, (4 Suppl 1), pp.47~48 (2015)
- Jabeen K, "Fluoroquinolone-resistant tuberculosis : implications in settings with weak healthcare systems", Int J Infect Dis, 32, pp.118~123 (2015)
- "Annual report on the notified tuberculosis patients in Korea 2014" (2015)[URL]